Literature DB >> 19031029

Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs.

Cees van Kooten1, Annelein S Stax, Andrea M Woltman, Kyra A Gelderman.   

Abstract

Dendritic cells (DCs) have a central role in immune regulation, ranging from tolerance induction to the induction of specific immune responses. DCs serve as an essential link between innate and adaptive immunity. This broad range of powerful immune stimulatory as well as regulatory functions has made DCs as targets for vaccine development strategies. One approach to promote the tolerogenicity of DCs is to suppress their maturation by pharmacological agents, including glucocorticoids (GCs). In the present chapter we will review GCs used in vitro with cultured DCs, applied in vivo, or used to generate tolerogenic DCs for cellular therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19031029     DOI: 10.1007/978-3-540-71029-5_11

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  14 in total

1.  Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.

Authors:  Vien Phan; Tomoki Ito; Muneo Inaba; Yoshiko Azuma; Kayoko Kibata; Noriko Inagaki-Katashiba; Akihiro Tanaka; Atsushi Satake; Shosaku Nomura
Journal:  Blood Adv       Date:  2020-08-11

2.  Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine.

Authors:  Vinu Krishnan; Xian Xu; Sonali P Barwe; Xiaowei Yang; Kirk Czymmek; Scott A Waldman; Robert W Mason; Xinqiao Jia; Ayyappan K Rajasekaran
Journal:  Mol Pharm       Date:  2012-11-29       Impact factor: 4.939

3.  Experimental study of the mechanism of tolerance induction in dexamethasone-treated dendritic cells.

Authors:  Yu-bo Gong; Yi-fei Huang; Yan Li; Gen-cheng Han; Yu-rong Li; Da-jiang Wang; Gai-ping Du; Ji-feng Yu; Jing Song
Journal:  Med Sci Monit       Date:  2011-05

4.  In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine.

Authors:  Prachi Vilekar; Vibhudutta Awasthi; Pallavi Lagisetty; Catherine King; Nathan Shankar; Shanjana Awasthi
Journal:  BMC Immunol       Date:  2010-12-10       Impact factor: 3.615

5.  Comparative study of clinical grade human tolerogenic dendritic cells.

Authors:  M Naranjo-Gómez; D Raïch-Regué; C Oñate; L Grau-López; C Ramo-Tello; R Pujol-Borrell; E Martínez-Cáceres; Francesc E Borràs
Journal:  J Transl Med       Date:  2011-06-09       Impact factor: 5.531

6.  NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment.

Authors:  Klára Dáňová; Anna Klapetková; Jana Kayserová; Anna Šedivá; Radek Špíšek; Lenka Palová Jelínková
Journal:  Oncotarget       Date:  2015-06-10

Review 7.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

8.  Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro.

Authors:  Thomas G Berger; Hendrik Schulze-Koops; Michaela Schäfer; Ester Müller; Manfred B Lutz
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

9.  A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines.

Authors:  Paulina García-González; Rodrigo Morales; Lorena Hoyos; Jaxaira Maggi; Javier Campos; Bárbara Pesce; David Gárate; Milton Larrondo; Rodrigo González; Lilian Soto; Verónica Ramos; Pía Tobar; María Carmen Molina; Karina Pino-Lagos; Diego Catalán; Juan Carlos Aguillón
Journal:  J Transl Med       Date:  2013-05-24       Impact factor: 5.531

Review 10.  Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.

Authors:  Georgina Flórez-Grau; Irati Zubizarreta; Raquel Cabezón; Pablo Villoslada; Daniel Benitez-Ribas
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.